Sincalide
Kinevac, Sincalide (sincalide) is a protein pharmaceutical. Sincalide was first approved as Kinevac on 1982-01-01. It is known to target cholecystokinin receptor type A and gastrin/cholecystokinin type B receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Kinevac, Sincalide
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sincalide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KINEVAC | Bracco Diagnostics | N-017697 RX | 1982-01-01 | 1 products, RLD, RS |
| SINCALIDE | MAIA Biotechnology | N-210850 RX | 2022-11-22 | 1 products, RLD, RS |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2805 | Injection, sincalide, 5 micrograms |
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 3 | 4 |
| Abdominal pain | D015746 | EFO_0003766 | R10.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | 1 | — | 2 | 6 |
| Syndrome | D013577 | — | — | — | — | 1 | — | 1 | 2 |
| Thyroid diseases | D013959 | — | E00-E07 | — | — | 1 | — | — | 1 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | 1 | — | — | 1 |
| Constipation | D003248 | — | K59.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatitis | D010195 | EFO_0000278 | K85 | 1 | 1 | — | — | 1 | 2 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | 1 | 1 | — | — | 1 | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | 1 | 2 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | 1 | 1 | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peptic esophagitis | D004942 | EFO_1001095 | — | 1 | — | — | — | — | 1 |
| Esophagitis | D004941 | HP_0100633 | K20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 4 | 4 |
| Feeding and eating disorders | D001068 | — | F50 | — | — | — | — | 2 | 2 |
| Ostomy | D010030 | — | — | — | — | — | — | 2 | 2 |
| Gallbladder diseases | D005705 | EFO_0003832 | K82.9 | — | — | — | — | 1 | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Ideal body weight | D056865 | — | — | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | — | 1 | 1 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 1 | 1 |
Show 17 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sincalide |
| INN | sincalide |
| Description | SINCALIDE |
| Classification | Peptide |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 25126-32-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1121 |
| ChEBI ID | — |
| PubChem CID | 32800 |
| DrugBank | DB09142 |
| UNII ID | M03GIQ7Z6P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CCKAR
CCKAR
CCKBR
CCKBR
Organism
Homo sapiens
Gene name
CCKAR
Gene synonyms
CCKRA
NCBI Gene ID
Protein name
cholecystokinin receptor type A
Protein synonyms
CCK-A receptor, CCK-AR, CCK1-R, cholecystokinin type 1 receptor, cholecystokinin type-A receptor, Cholecystokinin-1 receptor
Uniprot ID
Mouse ortholog
Cckar (12425)
cholecystokinin receptor type A (Q9DBV6)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 58,803 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
139 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use